person · Reporting owner

Jones Nicole S

Disclosed activity across 3 companies

Tapewire entity: 21248
SEC CIK: 0001492663

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cigna GroupCI · Entity 550	See Remarks	August 18, 2026	August 20, 2026
FTI CONSULTING, INCFCN · Entity 4028	Director	June 01, 2022	June 02, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cigna Group

Report date August 18, 2026 · Filed August 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	25,880	Reported balance After 2026-08-18 transaction · row 1 1 source row Row 1 · 2026-08-18 · Sale · Disposed 2,677 · Balance 25,880 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
Common Stock, $.01 Par ValueSEC Table I · non-derivative	IndirectBy 401(k)	1,451.2364	Reported balance Holding disclosure · report date 2026-08-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,451.2364 F2: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.

F2: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

FTI CONSULTING, INC

Report date June 01, 2022 · Filed June 02, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,809	Reported balance After 2022-06-01 transaction · row 1 1 source row Row 1 · 2022-06-01 · Grant · Acquired 1,492 · Balance 1,809 F1: The shares of restricted stock will vest in full on the first anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of restricted stock will vest in full on the first anniversary of the date of grant.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cigna Holding Co

Report date December 20, 2018 · Filed December 26, 2018

Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $.25 Par ValueSEC Table I · non-derivative	Direct	Reported balance After 2018-12-20 transaction · row 1 1 source row Row 1 · 2018-12-20 · Disposition to issuer · Disposed 26,700 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
Common Stock, $.25 Par ValueSEC Table I · non-derivative	IndirectBy 401(k)	Reported balance After 2018-12-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-12-20 · Disposition to issuer · Disposed 1,313.1308 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.73 · Expires 2023-03-05	Direct	Reported balance After 2018-12-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-12-20 · Disposition to issuer · Disposed 17,163 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.04 · Expires 2024-02-26	Direct	Reported balance After 2018-12-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-20 · Disposition to issuer · Disposed 36,316 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25	Direct	Reported balance After 2018-12-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-20 · Disposition to issuer · Disposed 22,509 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01	Direct	Reported balance After 2018-12-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-12-20 · Disposition to issuer · Disposed 20,342 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28	Direct	Reported balance After 2018-12-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-12-20 · Disposition to issuer · Disposed 17,666 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28	Direct	Reported balance After 2018-12-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-12-20 · Disposition to issuer · Disposed 14,484 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote)

F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3: This option was fully vested and exercisable at the time of the Merger.

F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.

F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.

F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.

F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 18, 2026 Filed Aug 20, 2026 21:07 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	2,677	$279.61	$748,515.97	Disclosure SEC source: 0001492663-26-000003 · wk-form4_1787260034.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,880 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. Read SEC document
August 05, 2026 Filed Aug 6, 2026 20:31 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,301	$0.00 Strike: $192.02	$0.00	Disclosure SEC source: 0001739940-26-000067 · wk-form4_1786048270.xml · derivative · entry 6 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 1,301 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. F3 · derivative.exercise_date: This option was granted on February 26, 2020. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 05, 2026 Filed Aug 6, 2026 20:31 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,301	$192.02	$249,818.02	Disclosure SEC source: 0001739940-26-000067 · wk-form4_1786048270.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. Read SEC document
August 04, 2026 Filed Aug 6, 2026 20:31 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	14,045	$0.00 Strike: $192.02	$0.00	Disclosure SEC source: 0001739940-26-000067 · wk-form4_1786048270.xml · derivative · entry 5 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,301 Underlying: Common Stock, $.01 Par Value · 14,045 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. F3 · derivative.exercise_date: This option was granted on February 26, 2020. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 04, 2026 Filed Aug 6, 2026 20:31 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	19,436	$276.27	$5,369,583.72	Disclosure SEC source: 0001739940-26-000067 · wk-form4_1786048270.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,256 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. Read SEC document
August 04, 2026 Filed Aug 6, 2026 20:31 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	14,045	$192.02	$2,696,920.90	Disclosure SEC source: 0001739940-26-000067 · wk-form4_1786048270.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026. Read SEC document
March 02, 2026 Filed Mar 4, 2026 00:18 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	2,307	$288.91	$666,515.37	Disclosure SEC source: 0001739940-26-000014 · wk-form4_1772583480.xml · nonDerivative · entry 5 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,647 F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:18 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	8,066	$0.00 Strike: $287.55	$0.00	Disclosure SEC source: 0001739940-26-000014 · wk-form4_1772583480.xml · derivative · entry 7 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,066 Underlying: Common Stock, $.01 Par Value · 8,066 shares Expires 2036-02-27 F7 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2027. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:18 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	912	$287.55	$262,245.60	Disclosure SEC source: 0001739940-26-000014 · wk-form4_1772583480.xml · nonDerivative · entry 4 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,954 F4 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:18 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	1,826	$287.55	$525,066.30	Disclosure SEC source: 0001739940-26-000014 · wk-form4_1772583480.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,866 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:18 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	5,234	$0.00	$0.00	Disclosure SEC source: 0001739940-26-000014 · wk-form4_1772583480.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,692 F2 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2027. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:18 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	4,133	$0.00	$0.00	Disclosure SEC source: 0001739940-26-000014 · wk-form4_1772583480.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,458 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:15 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,329	$0.00 Strike: $197.35	$0.00	Disclosure SEC source: 0001225208-25-007353 · doc4.xml · derivative · entry 10 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 1,329 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. F4 · derivative.exercise_date: This option was granted on February 28, 2018. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:15 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,348	$0.00 Strike: $183.44	$0.00	Disclosure SEC source: 0001225208-25-007353 · doc4.xml · derivative · entry 9 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 1,348 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. F3 · derivative.exercise_date: This option was granted on February 27, 2019. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:15 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,329	$197.35	$262,278.15	Disclosure SEC source: 0001225208-25-007353 · doc4.xml · nonDerivative · entry 5 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. Read SEC document
August 18, 2025 Filed Aug 19, 2025 21:15 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,348	$183.44	$247,277.79	Disclosure SEC source: 0001225208-25-007353 · doc4.xml · nonDerivative · entry 4 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. Read SEC document
August 15, 2025 Filed Aug 19, 2025 21:15 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	13,155	$0.00 Strike: $197.35	$0.00	Disclosure SEC source: 0001225208-25-007353 · doc4.xml · derivative · entry 8 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,329 Underlying: Common Stock, $.01 Par Value · 13,155 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. F4 · derivative.exercise_date: This option was granted on February 28, 2018. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 15, 2025 Filed Aug 19, 2025 21:15 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	11,598	$0.00 Strike: $183.44	$0.00	Disclosure SEC source: 0001225208-25-007353 · doc4.xml · derivative · entry 7 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,348 Underlying: Common Stock, $.01 Par Value · 11,598 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. F3 · derivative.exercise_date: This option was granted on February 27, 2019. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 15, 2025 Filed Aug 19, 2025 21:15 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	28,526	$300.00	$8,557,800.00	Disclosure SEC source: 0001225208-25-007353 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,648 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. Read SEC document
August 15, 2025 Filed Aug 19, 2025 21:15 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	11,598	$183.44	$2,127,542.92	Disclosure SEC source: 0001225208-25-007353 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. Read SEC document
August 15, 2025 Filed Aug 19, 2025 21:15 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	13,155	$197.35	$2,596,139.25	Disclosure SEC source: 0001225208-25-007353 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025. Read SEC document
March 03, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	4,904	$308.12	$1,511,020.48	Disclosure SEC source: 0001225208-25-002921 · doc4.xml · nonDerivative · entry 5 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,421 F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	11,176	$0.00 Strike: $305.86	$0.00	Disclosure SEC source: 0001225208-25-002921 · doc4.xml · derivative · entry 7 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,176 Underlying: Common Stock, $.01 Par Value · 11,176 shares Expires 2035-02-28 F7 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2026. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	4,160	$305.86	$1,272,377.60	Disclosure SEC source: 0001225208-25-002921 · doc4.xml · nonDerivative · entry 4 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,325 F4 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	949	$305.86	$290,261.14	Disclosure SEC source: 0001225208-25-002921 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,485 F3 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	3,147	$0.00	$0.00	Disclosure SEC source: 0001225208-25-002921 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,434 F2 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2026. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	9,064	$0.00	$0.00	Disclosure SEC source: 0001225208-25-002921 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,287 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2022-2024 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
August 13, 2024 Filed Aug 14, 2024 20:30 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,636	$0.00 Strike: $149.14	$0.00	Disclosure SEC source: 0001225208-24-008011 · doc4.xml · derivative · entry 6 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 2,636 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024. F3 · derivative.exercise_date: This option was granted on February 28, 2017. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 13, 2024 Filed Aug 14, 2024 20:30 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	2,636	$149.14	$393,119.86	Disclosure SEC source: 0001225208-24-008011 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:30 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	15,030	$0.00 Strike: $149.14	$0.00	Disclosure SEC source: 0001225208-24-008011 · doc4.xml · derivative · entry 5 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,636 Underlying: Common Stock, $.01 Par Value · 15,030 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024. F3 · derivative.exercise_date: This option was granted on February 28, 2017. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:30 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	22,030	$330.96	$7,291,048.80	Disclosure SEC source: 0001225208-24-008011 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,587 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:30 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	15,030	$149.14	$2,241,499.05	Disclosure SEC source: 0001225208-24-008011 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024. Read SEC document
March 04, 2024 Filed Mar 5, 2024 22:43 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	4,436	$332.62	$1,475,502.32	Disclosure SEC source: 0001225208-24-003710 · doc4.xml · nonDerivative · entry 4 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,587 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2023. Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:43 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	3,832	$333.36	$1,277,435.52	Disclosure SEC source: 0001225208-24-003710 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,023 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:43 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	1,139	$333.36	$379,697.04	Disclosure SEC source: 0001225208-24-003710 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,855 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:43 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	8,268	$0.00	$0.00	Disclosure SEC source: 0001225208-24-003710 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,994 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2021-2023 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 28, 2024 Filed Mar 2, 2024 00:44 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	9,677	$0.00 Strike: $336.48	$0.00	Disclosure SEC source: 0001225208-24-003417 · doc4.xml · derivative · entry 3 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,677 Underlying: Common Stock, $.01 Par Value · 9,677 shares Expires 2034-02-28 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2025. Read SEC document
February 28, 2024 Filed Mar 2, 2024 00:44 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	2,657	$0.00	$0.00	Disclosure SEC source: 0001225208-24-003417 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,726 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2025. Read SEC document
August 21, 2023 Filed Aug 23, 2023 21:19 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	7,819	$276.86	$2,164,768.34	Disclosure SEC source: 0001225208-23-008431 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,069 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2023. Read SEC document
March 02, 2023 Filed Mar 3, 2023 22:11 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	663	$289.00	$191,607.00	Disclosure SEC source: 0001225208-23-003382 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,888 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022. Read SEC document
March 01, 2023 Filed Mar 3, 2023 22:11 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	1,146	$289.44	$331,698.24	Disclosure SEC source: 0001225208-23-003382 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,551 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 27, 2023 Filed Feb 28, 2023 23:01 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	5,404	$294.06	$1,589,100.24	Disclosure SEC source: 0001225208-23-002992 · doc4.xml · nonDerivative · entry 4 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,697 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022. Read SEC document
February 24, 2023 Filed Feb 28, 2023 23:01 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	3,709	$294.27	$1,091,447.43	Disclosure SEC source: 0001225208-23-002992 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,101 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 24, 2023 Filed Feb 28, 2023 23:01 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	446	$294.27	$131,244.42	Disclosure SEC source: 0001225208-23-002992 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,810 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 24, 2023 Filed Feb 28, 2023 23:01 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	8,637	$0.00	$0.00	Disclosure SEC source: 0001225208-23-002992 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,256 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2020-2022 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 22, 2023 Filed Feb 25, 2023 02:12 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	10,459	$0.00 Strike: $294.61	$0.00	Disclosure SEC source: 0001225208-23-002824 · doc4.xml · derivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,459 Underlying: Common Stock, $.01 Par Value · 10,459 shares Expires 2033-02-22 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2024. Read SEC document
February 22, 2023 Filed Feb 25, 2023 02:12 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	2,831	$0.00	$0.00	Disclosure SEC source: 0001225208-23-002824 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,619 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2024. Read SEC document
June 01, 2022 Filed Jun 2, 2022 21:39 UTC	FTI CONSULTING, INC FCN · Entity 4028	GrantCommon Stock	1,492	$0.00	$0.00	Disclosure SEC source: 0000887936-22-000071 · wf-form4_165420594311528.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,809 F1 · shares: The shares of restricted stock will vest in full on the first anniversary of the date of grant. Read SEC document
May 18, 2022 Filed May 19, 2022 21:22 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	880	$0.00 Strike: $139.22	$0.00	Disclosure SEC source: 0001225208-22-007208 · doc4.xml · derivative · entry 6 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 880 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022. F3 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
May 18, 2022 Filed May 19, 2022 21:22 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	880	$139.22	$122,513.60	Disclosure SEC source: 0001225208-22-007208 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.